A new study conducted by researchers from the Washington University School of Medicine identified an experimental drug that ...

A study examining the long-term effects of anti-amyloid therapy gantenerumab suggests that full amyloid plaque removal may help reduce Alzheimer’s symptoms in individuals at risk for dominantly ...

Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with ...

The U.S. Food and Drug Administration has launched the "Chemical Contaminants Transparency Tool" (CCT Tool), an online ...

The drug, gantenerumab, was abandoned by its developers, but subsequent anti-amyloid drugs lecanemab ( Leqembi) and donanemab ...

A new international study has offered hope that Alzheimer’s disease may one day be preventable—at least in people genetically ...

An experimental drug has shown promise in preventing Alzheimer’s for people at higher risk of developing the disease.

Clinical trial of people destined to develop early-onset Alzheimer’s disease shows eliminating amyloid from brain.

Scientists report long-term gantenerumab use might prevent cognitive decline in people with genetic predisposition to ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...